TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05881837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection: dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection: dose level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection: dose level 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection Placebo
Description: Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
Study: NCT05027204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, Q3W, i.v. 30 min
Study: NCT06551597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extremely low frequency electromagnetic fields stimulation
Description: * In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extremely low frequency electromagnetic fields stimulation
Description: * In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation.
Study: NCT05894707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT650C
Description: Recombinant anti-IL-17A antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT650C
Description: Recombinant anti-IL-17A antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT650C
Description: Recombinant anti-IL-17A antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT650C
Description: Recombinant anti-IL-17A antibody
Study: NCT05978089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi tablet
Description: The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxinshi tablet simulants
Description: The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
Study: NCT06347848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation Focused on Reducing Internalized Stigma
Description: Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break.
Study: NCT04728802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide
Description: Proxalutamide 300mg q.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT05423132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: The patients will receive 15 ml of Ropivacaine 0.375 % on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum injection
Description: The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
Study: NCT06124898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcohol-related mobile health technologies
Description: Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcohol-related mobile health technologies
Description: Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.
Study: NCT06704724

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PF-07284892
Description: SHP2 Inhibitor
Study: NCT06725576

Intervention type: PROCEDURE
Intervention: Ablation
Description: Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
Study: NCT06726278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400mcg Tab
Description: Misoprostol 400 µg is a synthetic prostaglandin E1 analog used in this clinical trial to evaluate its effects in inducing uterine contractions or labor. This dosage form is typically administered orally, and its primary mechanism involves the softening and dilation of the cervix, making it a common choice in obstetric practices for labor induction. The study will evaluate its efficacy and safety profile when compared to the placebo group. Misoprostol is administered in a single dose of 400 µg, and participants will be monitored for any adverse reactions or labor-related outcomes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
Study: NCT04850170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: 1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy
Description: include the stretching of the neck, facial and oral movement training, and swallowing training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: include the stretching of the neck, facial and oral movement training, and swallowing training
Study: NCT05255939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal TRA group
Description: dTRA for PCI procedure to ACS patients.
Study: NCT04434885

Intervention type: OTHER
Intervention: Clinical and imaging examination of symptoms and signs suggestive of axial involvement
Description: Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
Study: NCT05233436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally
Study: NCT06725134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog presence
Description: A trained therapy dog will be present during the child's dental appointment. The dog will be in the operatory as the child enters the room and will lie on the child during injection of local anesthesia.
Study: NCT05255939

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional TRA group
Description: Conventional TRA for PCI procedure to ACS patients
Study: NCT05776407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is used for lymphodepletion.
Study: NCT06725134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care basic behavior guidance
Description: Basic behavior guidance as defined by the American Academy of Pediatric Dentistry includes strategies to help children cope through potentially stressful dental procedures. These strategies include tell-show-do, positive reinforcement, parental presence, and nitrous oxide/oxygen analgesia, among others.
Study: NCT05245227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Misoprostol
Description: Misoprostol 400 mcg sublingual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Oxytocin
Description: 40 units IV Oxytocin in 1000 mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Oxytocin
Description: 40 units IV Oxytocin in 1000 mL normal saline
Study: NCT06124898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview and psychoeducation on blood/breath alcohol concentration
Description: Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview and psychoeducation on blood/breath alcohol concentration
Description: Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower tech facilitation
Description: Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Higher tech facilitation
Description: Participants will use an app developed during the study that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control psychoeducation
Description: Brief 25/30-minute psychoeducation on a topic not related to alcohol use that will be developed in the course of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Attention control technology
Description: App or other form of technology that will be developed in the course of the study to deliver information not related to alcohol use
Study: NCT05233436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally
Study: NCT05383586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Music Therapy
Description: Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
Study: NCT06568510

Intervention type: PROCEDURE
Intervention: Continuous peripheral nerve block
Description: A perineurial catheter is placed to a nerve structure through a Touchy needle
Study: NCT05243160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication review
Description: The intervention consist of a medication review by a clinical pharmacologist.
Study: NCT05523115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heights Smart Supplement
Description: The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate
Study: NCT05138315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metamorphopsia quantification
Description: Alleye App and M.chart examinations will be performed pre- and postsurgically.
Study: NCT04887753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronisation abilities
Description: The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronisation abilities
Description: The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations.
Study: NCT05363189

Intervention type: PROCEDURE
Intervention: Venous augmentation
Description: Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein

Intervention type: PROCEDURE
Intervention: Traditional ERAS (enhanced recovery after surgery) protocol
Description: Pre-, peri-, and post-operative care as described in the ERAS protocol

Intervention type: PROCEDURE
Intervention: Sahlgrenska recovery protocol
Description: Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol

Intervention type: PROCEDURE
Intervention: No venous augmentation
Description: Traditional deep inferior epigastric artery perforator flap (DIEP)
Study: NCT05396144

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nitrous oxide
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Study: NCT05391633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded Maternal Voice
Description: 60-minute looped recording of maternal voice, played once daily for 14 total days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Recording
Description: 60-minute blank recording played once daily for 14 total days.
Study: NCT05590507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Audio Recordings
Description: A 5-minute audio file aimed to increase likelihood of experiencing positive affect associated with physical activity. Participants will listen to a mindfulness audio file at the beginning of each physical activity session they choose to engage in during weeks 2-4
Study: NCT05233436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265028
Description: PF-07265028 will be administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Administered subcutaneously
Study: NCT04947332

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auto-inoculation
Description: A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
Study: NCT06337812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Starch
Description: Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study.
Study: NCT05655949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium-90
Description: Injection of radiation microsphere beads
Study: NCT06327828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated computer-aided treatment (Digital Thyroid, DigiThy)
Description: Semi-automated computer-aided treatment based on a mathematical model

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Guiding methimazole therapy based on the treating physician's decision
Study: NCT05954000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Behavioral Change Techniques
Description: 1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon.
Study: NCT04713956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DAC)
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Study: NCT06407245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Snacks
Description: The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application.
Study: NCT05422001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose ketamine
Description: Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml
Study: NCT06407245

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Exercise
Description: The movement breaks will be individualized to exercise preferences and physical abilities (e.g., fitness, musculoskeletal issues) and adaptable to multiple environments (e.g., home, work) delivered via mobile phone application.